Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher (DHR) — Rule 144 notice of proposed sale. A holder filed to sell 600,000 shares of Danaher common stock through Monness, Crespi, Hardt & Co., Inc., with an aggregate market value of $128,406,000. The approximate sale date is 10/31/2025 on the NYSE.
The filing lists 706,349,563 shares outstanding. The seller originally acquired 1,900,000 shares on 06/11/2021 via a distribution from Capital Yield Corporation in connection with the liquidation of a closely held corporation.
Danaher Corporation reported Q3 results with sales of $6,053 million, up from $5,798 million a year ago. Operating profit rose to $1,154 million and net earnings increased to $908 million, delivering diluted EPS of $1.27 versus $1.12.
Year-to-date, sales reached $17,730 million and net earnings were $2,417 million. The effective tax rate was 15.6% for the quarter. By segment in Q3, Biotechnology generated $1,798 million of sales, Life Sciences $1,792 million, and Diagnostics $2,463 million. The company recorded $101 million of impairments in the quarter, primarily in Biotechnology and Diagnostics.
Cash from operating activities was $4,299 million for the nine-month period. Danaher repurchased $3,088 million of common stock year-to-date and repaid $500 million of notes on September 15, 2025. After quarter-end, it issued CHF 1,250 million of Swiss franc bonds for general corporate purposes. Shares outstanding were 706,349,563 as of October 16, 2025.
Danaher Corporation furnished an 8‑K announcing its third‑quarter results. On October 21, 2025, the company issued a press release for the quarter ended September 26, 2025, attached as Exhibit 99.1 and incorporated by reference. The information is furnished under Item 2.02 and is expressly stated as not deemed “filed” under Section 18 of the Exchange Act.
Danaher Corporation reported that its Board of Directors amended and restated the company’s By-laws effective September 9, 2025. The changes update the advance notice rules and related procedures that shareholders must follow to propose business or nominate directors at shareholder meetings, along with other routine, non-substantive revisions.
The Board also approved a new share repurchase program authorizing the company to buy back up to 35 million shares of its common stock. Repurchases may occur over time in open-market purchases, privately negotiated deals, or other methods, including trading plans under Rule 10b5-1. This authorization is in addition to existing repurchase authorizations, has no expiration date, and will remain in effect until suspended or terminated by the company.
Jonathan Leiken, identified as SVP - General Counsel of Danaher Corporation (DHR), submitted an initial Form 3 reporting the event dated 08/25/2025. The filing states that no securities are beneficially owned by Mr. Leiken (listed as 0 shares) and includes an exhibit referencing a Power of Attorney (Exhibit 24). The form was signed on behalf of Mr. Leiken by an attorney‑in‑fact, James F. O'Reilly, on 08/27/2025. This is an initial insider disclosure with no reported direct or derivative holdings.
Teri List, a director of Danaher Corporation (DHR), reported a sale of 2,778 shares of Danaher common stock on 08/22/2025 at a reported price of $211.058 per share. After the sale, the reporting person beneficially owned 20,750.672 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Danaher Corporation (DHR) Form 144 notice reports a proposed sale of 2,778 shares of common stock through Fidelity Brokerage Services LLC on 08/22/2025 on the NYSE with an aggregate market value of $586,319.96. The shares were acquired by stock option exercise from the issuer on 07/02/2025 and were paid for in cash on that date. The filing lists the total number of shares outstanding as 716,051,590. The form indicates no securities sold during the past three months for the account and includes the statutory representation that the seller has no undisclosed material adverse information.